SCHEMBL2565679

SCHEMBL2565679

NC(=O)Cc1nc2c[c]ccc2[nH]1

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAOB P27338 6/20 0.43
MAOA P21397 3/20 0.43
ALDH1A1 P00352 4/20 0.40
KDM4E B2RXH2 4/20 0.40
MAPT P10636 3/20 0.40
HSD17B10 Q99714 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
RAB9A P51151 4/20 0.39
NPC1 O15118 3/20 0.39
CHRM1 P11229 1/20 0.37
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
HTT P42858 1/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1663569 0.78 CHRM1 (0.64) ALDH1A1KDM4EMAPTCHRM1
SCHEMBL2207637 0.78 MAPT (0.63) ALDH1A1KDM4EMAPTHSD17B10SMN1; SMN2
SCHEMBL30343700 0.78 MAPT (0.63) ALDH1A1KDM4EMAPTHSD17B10SMN1; SMN2
SCHEMBL4468892 0.76 CYP3A4 (0.37) MAPTRAB9ANPC1CYP3A4
Hydrochloric Acid SCHEMBL2211742 0.76 ALDH1A1 (0.66) ALDH1A1KDM4EMAPTHSD17B10SMN1; SMN2
SCHEMBL19330024 0.76 DDAH1 (0.58) HSD17B10RAB9ANPC1HTT
SCHEMBL2564874 0.73 ALDH1A1 (0.53) ALDH1A1KDM4EMAPTTDP1
SCHEMBL7147057 0.73 MAOB (0.57) MAOBMAOARAB9ANPC1TDP1
SCHEMBL693868 0.72 CACNA1H (0.40) KDM4EMAPTSMN1; SMN2RAB9ANPC1
SCHEMBL698381 0.71 GAA (0.66) KDM4EMAPTSMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230026651-A1 AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS CYTOKINETICS, INC. 2023-01-26 US disclosed
US-11369565-B2 Amino-pyrimidine skeletal muscle modulators CYTOKINETICS, INC. (US) 2022-06-28 US disclosed
US-20210045997-A1 AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS CYTOKINETICS, INC. 2021-02-18 US disclosed
US-10765624-B2 Amino-pyrimidine skeletal muscle modulators CYTOKINETICS, INC. (US) 2020-09-08 US disclosed
EP-3698795-A1 CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE Cytokinetics, Inc. (US) 2020-08-26 EP disclosed
EP-3127540-B1 CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE CYTOKINETICS INC (US) 2020-01-29 EP disclosed
US-20190307677-A1 AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS CYTOKINETICS INC (US) 2019-10-10 US disclosed
EP-3127541-B1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE CYTOKINETICS INC (US) 2019-07-17 EP disclosed
US-20190167676-A1 METHODS FOR IMPROVING RESISTANCE TO SKELETAL MUSCLE FATIGUE CYTOKINETICS, INC. 2019-06-06 US disclosed
US-10272030-B2 Amino-pyrimidine skeletal muscle modulators CYTOKINETICS, INC. (US) 2019-04-30 US disclosed
US-20130143862-A1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE CYTOKINETICS, INC. 2013-06-06 US disclosed
US-20130123289-A1 CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE CYTOKINETICS, INC. (US) 2013-05-16 US disclosed
CN-103025331-A Certain amino-pyrimidines, compositions thereof and methods of use thereof CYTOKINETICS INC 2013-04-03 CN disclosed
CN-103002897-A Certain amino-pyridazines, compositions thereof, and methods of use thereof CYTOKINETICS INC 2013-03-27 CN disclosed
US-20130060025-A1 CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE ASHCRAFT LUKE W (US) 2013-03-07 US disclosed
EP-2560488-A1 CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE Cytokinetics, Inc. (US) 2013-02-27 EP disclosed
EP-2560653-A1 CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE Cytokinetics, Inc. (US) 2013-02-27 EP disclosed
US-20120289698-A1 CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE CYTOKINETICS, INC. 2012-11-15 US disclosed
WO-2011133920-A1 CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE CYTOKINETICS, INC. (US) 2011-10-27 WO disclosed
WO-2011133888-A1 CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE CYTOKINETICS, INC. (US) 2011-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11369565-B2 Amino-pyrimidine skeletal muscle modulators MUSK, PYGM, TNNC1 MAOB 1975/4885MAOA 3595/4885ALDH1A1 2521/4885
US-10765624-B2 Amino-pyrimidine skeletal muscle modulators MUSK, PYGM, TNNC1 MAOB 3073/4885MAOA 4237/4885ALDH1A1 3068/4885
US-20130143862-A1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE SLC7A1, F12, C5 MAOB 605/4885MAOA 1490/4885ALDH1A1 1962/4885
US-20230026651-A1 AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS MUSK, PYGM, TNNC1 MAOB 3073/4885MAOA 4237/4885ALDH1A1 3068/4885
US-10272030-B2 Amino-pyrimidine skeletal muscle modulators MUSK, PYGM, TNNC1 MAOB 3073/4885MAOA 4237/4885ALDH1A1 3068/4885
US-20190167676-A1 METHODS FOR IMPROVING RESISTANCE TO SKELETAL MUSCLE FATIGUE TNNC1, TNNI3, TNNT2 MAOB 914/4885MAOA 1163/4885ALDH1A1 3954/4885
US-20190307677-A1 AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS MUSK, PYGM, TNNC1 MAOB 3073/4885MAOA 4237/4885ALDH1A1 3068/4885
US-20210045997-A1 AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS MUSK, PYGM, TNNC1 MAOB 1975/4885MAOA 3595/4885ALDH1A1 2521/4885
US-20120289698-A1 CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE F12, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ZYX MAOB 927/4885MAOA 1723/4885ALDH1A1 1710/4885
US-20130060025-A1 CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE F12, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ZYX MAOB 927/4885MAOA 1723/4885ALDH1A1 1710/4885
US-20130123289-A1 CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE HPRT1, TYMP, TYMS MAOB 1141/4885MAOA 2311/4885ALDH1A1 1759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.